- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05228951
Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
Pyrotinib Maleate, Trastuzumab, SHR6390(Dalpiciclib) and Letrozole in Combination for Neoadjuvant Treatment of Stage II-III TPBC
NOAH study confirmed that trastuzumab combined with chemotherapy can significantly improve PCR compared with chemotherapy alone, and established the status of trastuzumab as a new adjuvant targeted therapy. The emergence of CDK4/6 inhibitors has brought hope to breast cancer patients resistant to endocrine therapy. studies have shown that pyrotinib maleate combined with CDK4/6 inhibitor can significantly inhibit the proliferation of HER2 positive breast cancer cell lines, reduce the activation of pAKT and pHER3, inhibit cell arrest in G0-G1 phase, and increase cell apoptosis. In the mouse model, pyrotinib maleate combined with CDK4/6 inhibitor exhibits higher anti-tumor activity than any anti-tumor drug alone. Moreover, the toxicity of the combined therapy does not increase compared with monotherapy. This provides a good preclinical model for the treatment of breast cancer by pyrotinib maleate combined with CDK4/6 inhibitor.
In addition, NeoALTTO study、CALGB 40601 study、NSABP B-41 study confirmed that the clinical efficacy of lapatinib combined with trastuzumab combined chemotherapy was better than that of lapatinib or trastuzumab single target treatment group. Therefore, it is envisaged that the combination of pyrotinib maleate and dalpiciclib combined with letrozole on the basis of adding new trastuzumab to treat triple positive breast cancer will further improve the curative effect.
In conclusion, we believe that pyrotinib maleate combined with trastuzumab, dalpiciclib and letrozole can provide better strategies for neoadjuvant therapy in patients with II-III three positive breast cancer.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Nan Niu, MD
- Número de telefone: +8618940256668
- E-mail: niunannancy@163.com
Locais de estudo
-
-
Liaoning
-
Shenyang, Liaoning, China, 110004
- Recrutamento
- Shengjing Hospital of China Medical University
-
Contato:
- Nan Niu, MD
- Número de telefone: +8618940256668
- E-mail: niunannancy@163.com
-
Investigador principal:
- Cai-Gang Liu, PHD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Women aged≥18 years and ≤75 years meeting one of the following conditions;
- Those previously receiving ovariectomy, or aged ≥60 years
- Those aged < 60 years who have had 12 consecutive months of amenorrhoea without any pathological or physical causes, and have postmenopausal E2 and follicle stimulating hormone (FSH) levels
- Premenopausal or perimenopausal women who are willing to receive LHRH agonist treatment during the study period
- Women who have breast cancer histopathologically confirmed by positive estrogen receptor (ER; >10%), positive progesterone receptor (PR; >1%), and positive human epidermal growth factor receptor 2 (HER2) according to the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) human epidermal growth factor receptor 2 (HER2) guideline. ER, PR and HER2 will be assessed by immunohistochemistry (IHC) on harvested tissue. ER, PR and HER2 will be considered positive if the IHC result is positive (score 3+), or the IHC result is positive (2+) and in situ hybridization (ISH) amplification rate (≥2.0);
- Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time;
- Karnofsky Performance Status (KPS) Scale score ≥70;
The functional level of organs must meet the following requirements:
a) Bone marrow function i) Absolute neutrophil count(ANC)≥1.5×109/L (no use of growth factor within 14 days) ii) Platelet count(PLT)≥100×109/L (no corrective treatment within 7 days) iii) Hemoglobin level(Hb)≥100 g/L (no corrective treatment within 7 days) b) Liver and kidney function i) Total bilirubin(TBIL)≤1.5 upper limit of normal value (ULN) ii) Alanine transaminase (ALT) and aspartate transaminase (AST) ≤3×ULN iii) Blood urea nitrogen (BUN) and creatinine ≤1.5×ULN and creatinine clearance≥50 mL/min (Cockcroft-Gault formula); c) Color Doppler echocardiography: Left ventricular ejection fraction ≥50% d) 12-lead electrocardiography: QTc interval ≤480 ms
- Women who can undergo a biopsy;
- Volunteers to participate in the study, provision of signed informed consent, good compliance and willingness to cooperate with follow-ups.
Exclusion Criteria:
- Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy);
- Those who have received other anti-tumor drug treatments concurrently;
- Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer;
- Those who have stage IV breast cancer;
- Those who have breast cancer not histopathologically confirmed;
- Those who have other malignant tumors (with the exception of healed cervical carcinoma in situ) occurring in the past 5 years;
- Those who have severe dysfunction of the heart, liver, kidney, and other major organs;
- There are multiple factors that affect drug administration and absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction;
- Those who have participated in other clinical drug trials in the past 4 weeks;
- Those who are known to have a history of allergy to the component of study drugs; those who have a history of immunodeficiency, including positive detection of human immunodeficiency virus, hepatitis C virus, active hepatitis B or other acquired, congenital immunodeficiency diseases, or organ transplantation;
- Those who had suffered from any heart disease, including arrhythmia which requires drug treatment or is of clinical significance; myocardial infarction; heart failure; and any other heart disease judged by the investigator as unsuitable for this trial;
- Pregnant and lactating women; fertile women who provide positive results of baseline pregnancy test; women of childbearing age who are unwilling to take effective contraceptive measures during the whole study period;
- If the accompanying diseases (including, but not limited to, severe hypertension, severe diabetes, and active infection, which cannot be controlled by drugs) that would be a potential hazard to participant's health, or affect the completion of the study as per investigator's judgement;
- A clear history of neurological or psychiatric disorders, including epilepsy or dementia. Upon the suggestion of the investigators for other reasons
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole
After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole.
The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles.
If the disease progresses, the participant will withdraw from the trial.
If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment.
The patients will be followed up for 5 years.
|
After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor dalpiciclib, trastuzumab and letrozole.
The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles.
If the disease progresses, the participant will withdraw from the trial.
If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment.
The patients will be followed up for 5 years.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Total pathological complete response (tpCR)
Prazo: 1 month to 5 years after surgery
|
tpCR is defined as the absence of residual invasive cancer on resected breast specimen and the sampled regional lymph nodes as shown by hematoxylin-eosin staining after completion of the neoadjuvant treatment
|
1 month to 5 years after surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Carga residual de câncer (RCB)
Prazo: 1 mês a 5 anos após a cirurgia
|
O escore RCB é obtido de acordo com a avaliação patológica após a conclusão do tratamento neoadjuvante e da cirurgia
|
1 mês a 5 anos após a cirurgia
|
Best overall response rate (BORR)
Prazo: During neoadjuvant treatment(1-5 months of treatment)
|
The proportion of patients who respond to the treatment at any study time point
|
During neoadjuvant treatment(1-5 months of treatment)
|
Breast pathologic complete response (bpCR)
Prazo: 1 month to 5 years after surgery
|
There was no invasive carcinoma in the primary breast lesions (ypT0-is)
|
1 month to 5 years after surgery
|
Overall survival (OS)
Prazo: Within 5 years after surgery
|
It refers to the length of time from the start of treatment to the death of the patient
|
Within 5 years after surgery
|
Disease-free survival (DFS)
Prazo: Within 5 years after surgery
|
It refers to the length of time from the start of medication after enrollment to the death of the patient because of the recurrence, distant metastasis of the disease, invasive contralateral breast cancer, or any other cause
|
Within 5 years after surgery
|
Subject safety
Prazo: From signing the informed consent to 28 days after last dose
|
Number of Adverse Events using NCI CTCAE 5.0
|
From signing the informed consent to 28 days after last dose
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Cai-Gang Liu, PHD, Shengjing Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças de pele
- Neoplasias
- Neoplasias por local
- Doenças da mama
- Neoplasias da Mama
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Hormônios, Substitutos Hormonais e Antagonistas Hormonais
- Agentes Antineoplásicos Imunológicos
- Antagonistas Hormonais
- Inibidores de Aromatase
- Inibidores da Síntese de Esteróides
- Antagonistas de Estrogênio
- Trastuzumabe
- Letrozol
Outros números de identificação do estudo
- Shengjing-LCG011
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de mama
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
Ensaios clínicos em Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole
-
First Affiliated Hospital of Zhejiang UniversityRecrutamentoCâncer de mama | Câncer de Mama HER2-positivo | Tumor positivo para receptor de estrogênioChina
-
Fengzhi FengRecrutamentoCarcinoma ovariano recorrenteChina
-
Shuangyue LiuAinda não está recrutando
-
The Affiliated Hospital of Qingdao UniversityJiangsu HengRui Medicine Co., Ltd.Ainda não está recrutando
-
Fujian Medical University Union HospitalAinda não está recrutandoCâncer de Mama Avançado
-
Yantai Yuhuangding HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Recrutamento
-
Hebei Medical University Fourth HospitalAinda não está recrutando
-
Fudan UniversityJiangsu HengRui Medicine Co., Ltd.Ativo, não recrutando
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJiangsu HengRui Medicine Co., Ltd.RecrutamentoCâncer de Mama MetastáticoChina
-
Shengjing HospitalRecrutamento